Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today

After unveiling positive results for its lead drug, sacituzumab govitecan, in breast cancer at the influential American Society of Clinical Oncology (ASCO) conference, shares in Immunomedics(NASDAQ:IMMU) rallied by as much as 14.7% today before settling in for a gain of 9.3% at 3 p.m. EDT.